Evidence map›Paper›PMID 39673665›Full record

ReviewMedical oncology (Northwood, London, England)2024

Sorcin: mechanisms of action in cancer hallmarks, drug resistance and opportunities in therapeutics.

Sushmita Ghosh, Arpana Sharma, R Suresh Kumar, Vilas Nasare

Abstract readReview
PubMed Publisher
In one paragraph

Review in Medical oncology (Northwood, London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Sushmita GhoshDepartment of Pathology and Cancer Screening, Chittaranjan National Cancer Institute, Kolkata, India.
Arpana SharmaDepartment of Pathology and Cancer Screening, Chittaranjan National Cancer Institute, Kolkata, India.
R Suresh KumarMolecular Biology Division, National Institute of Cancer Prevention and Research, ICMR, Noida, Delhi, India.
Vilas NasareDepartment of Pathology and Cancer Screening, Chittaranjan National Cancer Institute, Kolkata, India. vilas.dr@gmail.com.ORCID http://orcid.org/0000-0002-0016-9610

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Soluble resistant related calcium binding protein (Sorcin) plays an important role in tumor progression, angiogenesis, metastasis, and multidrug resistance. Differential expression of Sorcin across different cancers significantly correlates with key clinicopathological characteristics and survival outcomes, underscoring its potential as a prognostic marker. Its involvement in drug-resistant cancers further advert Sorcin as a promising therapeutic target. This review summarizes the mechanistic role of Sorcin in cancer, its contribution to drug resistance, clinical relevance, and the current and emerging therapeutic approaches aimed at translating Sorcin-targeted therapies into clinical practice.

Indexed as

Calcium-Binding ProteinsDrug Resistance, NeoplasmNeoplasmsAnimalsAntineoplastic AgentsHumansAntineoplastic AgentsCalcium-Binding ProteinsSRI protein, humanCancerClinicopathologyMultidrug resistanceSignaling pathwaysSorcinTherapeutics

Identifiers

PMID39673665

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.